Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance
Open accessThe DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index; 71 of the 195 sources its claims cite were checked for support.
Abstract
Adipose tissue (AT) represents a plastic organ that can undergo significant remodeling in response to metabolic demands. With its numerous checkpoints, the incretin system seems to play a significant role in controlling glucose homeostasis and energy balance. The importance of the incretin hormones, namely the glucagon-like peptide-1 (GLP-1) and the glucose-dependent insulinotropic peptide (GIP), in controlling the function of adipose cells has been brought to light by recent studies. Notably, a “paradigm shift” in reevaluating the role of the incretin system in AT as a potential target to treat obesity-linked metabolic disorders resulted from the demonstration that a disruption of the GIP and GLP-1 signaling axis in fat is associated with adiposity-induced insulin-resistance (IR) and/or type 2 diabetes mellitus (T2D). We will briefly discuss the (patho)physiological functions of GLP-1 and GIP signaling in AT in this review, emphasizing their potential impacts on lipid storage, adipogenesis, glucose metabolism and inflammation. We will also address the conundrum with the perturbation of the incretin axis in white or brown fat tissue and the emergence of metabolic disorders. In order to reduce or avoid adiposity-related metabolic complications, we will finally go over a potential scientific rationale for suggesting AT as a novel target for GLP-1 and GIP receptor agonists and co-agonists.
Overview
CoChat Summary
TL;DR
This narrative review argues that adipose tissue is a direct target of the incretin axis, proposing that disrupted GLP-1 and GIP signaling in fat contributes to obesity-linked insulin resistance and type 2 diabetes. It synthesizes receptor-expression, mechanistic, and clinical evidence to support repositioning adipose tissue as a therapeutic target for incretin-based drugs and co-agonists.
Key findings
- GLP-1 receptors are expressed in both mature adipocytes and the stromal vascular fraction of human adipose tissue; GLP-1R expression in visceral fat is up-regulated in morbid obesity with a high degree of insulin resistance, while subcutaneous expression does not differ by IR degree, suggesting a possible compensatory mechanism.
- GLP-1 has dose-dependent, opposing effects on adipocytes: lipogenic action predominates at picomolar concentrations and lipolytic action at nanomolar doses; GLP-1 also promotes pre-adipocyte differentiation, inhibits apoptosis, and increases insulin-dependent glucose uptake via GLUT4 up-regulation.
- GIP receptors are present on fat cells; GIP facilitates glucose uptake, lipoprotein lipase activity and lipogenesis, and GIP-R expression increases with adipocyte differentiation. GIP-R expression is down-regulated in subcutaneous adipose tissue of obese individuals and negatively associated with BMI, waist circumference, systolic blood pressure, glucose and TAG values.
- A meta-analysis of 10 trials found GLP-1 RA treatment reduced visceral adipose tissue by 11.2% versus 8.3% for subcutaneous adipose tissue in patients with T2D.
- Weight loss with GLP-1 RAs is more pronounced in females than males; women had 32% higher liraglutide exposure than men at similar weights, and GI adverse events (more common in females) are associated with greater weight reduction.
- Human studies of liraglutide (1.8 mg/day, 26 weeks) and exenatide found no significant reduction in supraclavicular brown adipose tissue fat fraction, and REE was reduced or unchanged.
Methods
- Narrative review; no primary data collection or systematic search protocol is described.
- Synthesizes preclinical (cell culture, rodent) and human evidence on GLP-1/GIP receptor expression and action in white, brown and beige adipose tissue, plus clinical trial and meta-analytic data on GLP-1 RA effects on fat depots, sex differences, and cancer risk.
- Includes discussion of incretin signaling mechanisms (cAMP/PKA/EPAC2, ERK-1/2, β-arrestin, Gαq/PKC pathways) and hepatic, skeletal muscle and adipose actions.
Limitations
- The paper states that molecular mechanisms of incretin action are "complex, cell-specific, and not fully understood," and that data on GLP-1 and GIP effects in skeletal muscle are "still scant" with mechanisms "basically unclear."
- The authors note that findings on GLP-1R expression in adipose tissue are pertinent only to individuals with morbid obesity and T2D and cannot be generalized to non-morbidly obese or overweight subjects with insulin resistance; GLP-1R expression in adipose tissue was not useful for predicting diabetes remission, IR improvement or weight loss after bariatric surgery.
- The authors state that conflicting findings on GIP actions in adipose tissue are at odds with recent clinical results and may reflect missing tools to evaluate long-term GIP-R stimulation effects; the paradoxical similar metabolic effects of GIP agonists and antagonists "remain to be resolved."
- Evident from the text: as a narrative review without a stated systematic search strategy, selection of cited evidence is not transparently reproducible.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
61 Valid · 9 Not valid · 88 Not checked · 34 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Currently, the literature provides conflicting evidence about a sexual dimorphism on the anti-hyperglicemic effect of GLP-1 RAs in subjects with T2D.”
§ Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance > 6. Expression and Activity of GLP-1 Receptors in Adipose Tissue > 6.2. Sex Differences in Response to GLP-1 RA Therapy in Type 2 Diabetes and Obesity: Prefential Effects in Subcutaneous vs. Visceral Fat Depot
What the sources say
- Disputedcites [85] Gallwitz, 2018, Effect of once-weekly dulaglutide on glycated haemoglobin (Hba1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c, Diabetes Obes. Metab. sourceExperimental — accuracy not yet measured
Our copy characterises the GLP‑1 RA sex-difference literature on glycaemic efficacy as concordant, not conflicting: the DISCUSSION states that the gender-independent HbA1c improvements 'are consistent with results observed in the subgroup analyses of exenatide twice daily, exenatide once weekly, and lixisenatide', that a liraglutide real-practice study 'also showed no differences in HbA1c reductions between women and men, consistent with our findings', and that no HbA1c difference was seen in Japanese dulaglutide patients. The Abstract Conclusions and the DISCUSSION opening likewise report significant glycaemic improvement 'irrespective of gender', with similar LS-mean HbA1c reductions in men and women at 6 and 12 months (RESULTS, HbA1c/FBG by gender). The only sex-specific signal the paper reports is in body weight (numerically greater loss in women, with a leptin-interaction hypothesis and a call for future investigation), which is not the anti-hyperglycaemic effect the claim describes; no passage in our copy says the evidence on glycaemic dimorphism is conflicting. (LLM, conf=0.70)
Checked by a reasoning model — may be wrong.
- Not checked yetcites [86] Quan, 2016, Gender-related different effects of a combined therapy of Exenatide and Metformin on overweight or obesity patients with type 2 diabetes mellitus, J. Diabetes Its Complicat. source
- Partly supportedcites [87] Durden, 2016, Predictors of glycemic control and diabetes-related costs among type 2 diabetes patients initiating therapy with liraglutide in the United States, J. Med. Econ. sourceExperimental — accuracy not yet measured
Our copy does address sexual dimorphism in the glycemic effect of a GLP-1 RA in T2D: the Predictors of glycemic control section (Table 4 discussion) reports females were more likely than males to achieve A1C ≤7% (OR = 1.75; p<0.05), and the Discussion notes an age-dependent gender effect, with younger women achieving higher rates of control. However, the paper never characterises the wider literature as conflicting or inconsistent on this point — it reports its own single-direction finding in 417 US commercially insured liraglutide initiators and does not review or contrast prior studies on sex differences with GLP-1 RAs. So the 'sexual dimorphism in anti-hyperglycemic effect of GLP-1 RAs in T2D' element is supported, but the attribution of 'conflicting evidence in the literature' is not made by this source. (LLM, conf=0.70)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Additionally, it has been suggested that the inhibition of new adipose cell formation is a trigger for the development of insulin resistance (IR), principally in the subcutaneous (sc) fat depots (i.e., abdominal and tight fat).”
§ Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance > 1. The Remodeling of Adipose Tissue
What the sources say
- Not checked yetcites [4] Danforth, 2000, Failure of adipocyte differentiation causes type II diabetes mellitus?, Nat. Genet. source
- Partly supportedcites [5] Sethi, 2010, Activatin’ human adipose progenitors in obesity, Diabetes sourceExperimental — accuracy not yet measured
Sethi's commentary does endorse the underlying idea: the opening section lays out the 'adipose tissue expandability hypothesis' (limit on safe triglyceride storage → ectopic fat → 'lipotoxicity and metabolic dysregulation of peripheral tissues', and 'similar metabolic consequences may also be predicted... when there is a paucity of adipose tissue'), and the section on adipose cellularity notes obese diabetics have 'fewer but larger adipocytes' with an inverse correlation between preadipocyte differentiation capacity and BMI (refs 5-7), while the summary states 'limitations in fat storage can lead to metabolic disorders'. However, our copy never names insulin resistance as the specific outcome, and it never attributes the phenomenon 'principally' to subcutaneous depots — subcutaneous appears only in the titles of cited works (refs 5, 6) and in Zaragosi et al.'s observation that activin A localizes to SVFs of omental, subcutaneous AND mesenteric depots. The depot specificity and the insulin-resistance endpoint in the citing sentence go beyond what this source states. (LLM, conf=0.72)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Adipose tissue (AT) represents a plastic organ that can undergo significant remodeling in response to metabolic demands.”
- Also stated in: § 1. The Remodeling of Adipose Tissue · boosted
“Adipose tissue (AT) is considered as a remarkably active and plastic organ with functional pleiotropism and elevated remodeling capacity [1,2].”
§ Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance > Abstract
What the sources say
- Not checked yetcites [1] Cypess, 2022, Reassessing human adipose tissue, N. Engl. J. Med. source
- Supportedcites [2] De Fano, M., Bartolini, D., Tortoioli, C., Vermigli, C., Malara, M., Galli, F., and Murdolo, G. (2022). Adipose tissue plasticity in response to pathophsyiological cues: A connecting link between obesity and its associated comorbidities. Int. J. Mol. Sci., 23. source
The Abstract (p. 1) states verbatim that 'Adipose tissue (AT) is a remarkably plastic and active organ with functional pleiotropism and high remodeling capacity,' and Section 2 ('The adipose tissue: a remarkably active and plastic "organ"') reiterates the high remodeling capacity, describing remodeling that 'orchestrates nutritional adaptations in response to variations of energy balance' — i.e., in response to metabolic demands. The citing sentence is a faithful paraphrase of this framing, which the paper itself develops throughout Sections 2 and 3. (LLM, conf=0.90)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 1. The Remodeling of Adipose Tissue · boosted
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“It has been shown that nonobese subjects with type 2 diabetes mellitus (T2D) and nondiabetic subjects with a genetic predisposition for T2D (first-degree relatives: FDR) have an unwarranted hypertrophic expansion of subcutaneous adipose tissue (SAT) [10].”
§ Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance > 1. The Remodeling of Adipose Tissue
What the sources say
- Partly supportedcites [10] Arner, P., Arner, E., Hmmarstedt, A., and Smith, U. (2011). Genetic predisposition for type 2 diabetes, but not for overweight/obesity, is associated with a restricted adipogenesis. PLoS ONE, 6. sourceExperimental — accuracy not yet measured
Our copy of Arner et al. 2011 fully supports the hereditary arm: the Results (Fat cell size in relation to body fat; Phenotypic characterization) and Discussion state that non-obese individuals with a genetic predisposition for T2D (recruited as first-degree relatives, Materials and Methods > Subjects) show inappropriately enlarged abdominal (subcutaneous, per Methods) fat cells with raised delta-values, i.e. unwarranted hypertrophic expansion. The other arm of the claim — nonobese subjects who actually HAVE type 2 diabetes — is not a study population of this paper: the Subjects section lists only T2D-heredity, obesity-heredity and control cohorts (164 lean, 500 overweight/obese; 166 Gothenburg FDRs), with no diabetic patients measured. The Introduction mentions adipose-cell hypertrophy in patients with Type 2 diabetes only to credit it to other works ([13], [14]) and to prior papers of theirs ([10], [11], [15]). (LLM, conf=0.78)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“This provocative concept (“expandability hypothesis”) justifies in part the seeming paradox of an increased risk of IR under circumstances when body fat is both reducing (i.e., lipodystrophy) and expanding (i.e., adiposity) [4,5].”
§ Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance > 1. The Remodeling of Adipose Tissue
What the sources say
- Not checked yetcites [4] Danforth, 2000, Failure of adipocyte differentiation causes type II diabetes mellitus?, Nat. Genet. source
- Supportedcites [5] Sethi, 2010, Activatin’ human adipose progenitors in obesity, Diabetes source
The opening section of our copy ("Activatin' Human Adipose Progenitors in Obesity," p. 1) names the "adipose tissue expandability hypothesis" as a "seemingly counterintuitive hypothesis" and states that adipose mass accumulation per se may not be directly causative, that expansion has a limit beyond which ectopic fat deposition causes lipotoxicity and metabolic dysregulation, and then that "similar metabolic consequences may also be predicted ... when there is a paucity of adipose tissue" — i.e., the same metabolic risk at both the expanding (adiposity) and reducing (lipodystrophy/paucity) extremes, which is exactly the paradox the citing sentence attributes to it. The closing paragraph ("limitations in fat storage can lead to metabolic disorders") reinforces this. Minor wording gap: our copy frames the outcome as "metabolic dysregulation/obesity-related metabolic abnormalities" and diabetes rather than using the term "insulin resistance" explicitly, but the substance is the same. The hypothesis is discussed and relied upon in the author's own text (with reference 1, Sethi & Vidal-Puig 2007, cited as background), so this is not a mere credit-to-another-work case. (LLM, conf=0.85)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
93 more claims · 50 with their cited sources checked
Create a free account to see all 192 claims and to verify the 124 references still open.
- It may state two separate claims as one. 72
- Probably not a substantial claim. 36
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Incretin-based agents induce significant weight loss, comparable to bariatric surgery, predominantly targeting adipose tissue.”
From Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review (2025) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Through these mechanisms, incretin-based medications promote body weight reduction primarily by targeting AT [6].”
From Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review (2025) · cites this paper as [6]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance > 5. GLP-1 and GIP Actions in Liver and Skeletal Muscle
“O’Harte et al. showed that GIP enhanced glucose transport in the mouse diaphragm [56].”
§ Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance > References
“Gastric inhibitory polypeptide and effects of glycation on glucose transport and metabolism in isolated mouse abdominal muscle”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance > 8. The Fine-Tuning of GLP-1/GLP1-R and GIP/GIP-R Axis in Fat: How to Reconcile This Challenging Puzzle?
“the protective role of GLP1-R activation by promoting adipogenesis and increasing the capacity of adipose cells to store lipids, thus decreasing ectopic lipid overflow and enhancing IR.”
§ Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance > 6. Expression and Activity of GLP-1 Receptors in Adipose Tissue > 6.1. White Adipose Tissue and GLP-1R Expression in Adipocytes and Stroma Vascular Fraction: A Depot-Dependent Difference?
“the promotion of adipogenesis through the activation of GLP-1R enhances the capacity of visceral hypertrophic adipocytes to store lipids, thus decreasing the ectopic lipid store and improving IR”
Citations
Cites
The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“Furthermore, GLP-1 and exendin-4 (a GLP-1 R agonist) stimulate glycogen synthase activity and glucose metabolism in rat soleus muscle and human skeletal muscle [54].”
BackgroundSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236 · cited 1×
“…impact on body weight [20], appetite [21], gastric emptying [22] and, moreover, some of these (liraglutide, dulaglutide, semaglutide sc) have shown a crucial cardiovascular protective effect in specific Cardiovascular Outcome Trials (CVOTs), both in subjects with T2D [23] and obesity [24].”
BackgroundSubcutaneous and visceral adipose tissue: their relation to the metabolic syndrome
Wajchenberg, B. L. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.6.0415 · Cited by 2,961 · cited 1×
“It is commonly known that an increase in abdominal VAT is associated with a raised risk of cardio-metabolic issues and an increased ability to predict death [71,72].”
BackgroundDynamics of fat cell turnover in humans
Spalding, K. L., Arner, E., Westermark, P. O., Bernard, S., Buchholz, B. A., Bergmann, O., Blomqvist, L., Hoffstedt, J., Näslund, E., Britton, T., et al. (2008) · Nature · doi:10.1038/nature06902 · Cited by 2,357
Subcutaneous and visceral adipose tissue: Structural and functional differences
Ibrahim, M. M. (2010) · Obesity Reviews · doi:10.1111/j.1467-789x.2009.00623.x · Cited by 2,238 · cited 1×
“It is commonly known that an increase in abdominal VAT is associated with a raised risk of cardio-metabolic issues and an increased ability to predict death [71,72].”
BackgroundSex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus
Kautzky-Willer, A., Harreiter, J., & Pacini, G. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1137 · Cited by 2,043
Human epicardial adipose tissue is a source of inflammatory mediators
Mazurek, T., Zhang, L., Zalewski, A., Mannion, J. D., Diehl, J. T., Arafat, H., Sarov-Blat, L., O’Brien, S., Keiper, E. A., Johnson, A. G., et al. (2003) · Circulation · doi:10.1161/01.cir.0000099542.57313.c5 · Cited by 1,966 · cited 1×
“Surprisingly, an excess of epicardial fat has been linked to IR and cardiovascular disorders, significantly influencing atherosclerosis through the paracrine release of pro-inflammatory cytokines [70].”
BackgroundAdipose tissue remodeling and obesity
Sun, K., Kusminski, C. M., & Scherer, P. E. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45887 · Cited by 1,941 · cited 1×
“It is theoretically possible for “healthy”, “unhealthy” or pathological processes to cause AT accrual [6].”
BackgroundNauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651 · cited 1×
“Additionally, due to their insulinotropic action, incretin hormones regulate glucagon release: GIP has been found to stimulate glucagon secretion, particularly at lower glucose values [14], whereas GLP-1 suppresses glucagon release and, consequently, reduces hepatic glucose production [15].”
Background
Research works printed but not linked: 1
- Finan, 2016, Reapprisal of GIP pharmacology for metabolic disease, Trends Endocrinol. Metab., 22, 359
Cited by
Spotlight on the Mechanism of Action of Semaglutide
Papakonstantinou, I. P., Tsioufis, K. P., & Katsi, V. K. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46120872 · Cited by 102
“…important, rendering any incapacity to engage new adipose cells to store excess lipids in the SAT as a preamble to the hypertrophic (unhealthy) growth of WAT, which is further characterized by an accrual infiltration of macrophages, extensive fibrosis, limited angiogenesis and ongoing hypoxia [63].”
Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss
Reiss, A. B., Gulkarov, S., Lau, R., Klek, S. P., Srivastava, A., Renna, H. A., & De Leon, J. (2025) · Biomolecules · doi:10.3390/biom15030408 · Cited by 58
“The energy-dense nature of fat makes it an efficient means of storing excess energy intake and thus the body favors fat for keeping energy in reserve [91,92].”
Incretin-Based Therapies Through the Decades: Molecular Innovations and Clinical Impact
Lee, A. A., Khotina, V. A., Kashirskikh, D. A., Voronko, O. E., Gasanov, V. A. O., & Vasiliev, A. V. (2025) · Medical Sciences · doi:10.3390/medsci13040269 · Cited by 26
Barana, L., De Fano, M., Cavallo, M., Manco, M., Prete, D., Fanelli, C. G., Porcellati, F., & Pippi, R. (2025) · Nutrients · doi:10.3390/nu18010131 · Cited by 13
“Through these mechanisms, incretin-based medications promote body weight reduction primarily by targeting AT [6].”
Relationship between hepatic lipid accumulation and type 2 diabetes mellitus
Wang, Z., Zan, W., Fan, Z., & Wang, S. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118723 · Cited by 8
Metadata
- Authors
- De Fano, M., Malara, M., Vermigli, C., & Murdolo, G.
- Affiliations
- Complex Structure of Endocrinology and Metabolism, Department of Medicine, Azienda Ospedaliera Santa Maria Misericordia, Ospedale di Perugia, 06081 Perugia, Italy
- Azienda Ospedaliera di Perugia (IT)
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2024-08-08
- Volume
- 25
- Issue
- 16
- Pages
- 8650
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC11354636
- OpenAlex
- W4401412316
- Semantic Scholar
- a274b0ccdc198095a25a52b5310ccb7a682841da
- Cited by
- 17
- References
- 138
- Citations by year
- 2026: 5 · 2025: 11 · 2024: 1
- FWCI
- 1.12
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- adipose tissue, incretin system, glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, insulin resistance, obesity, type 2 diabetes, adipose tissue remodeling, adipogenesis, fat deposition, glucose metabolism, adipose tissue inflammation, brown adipose tissue, white adipose tissue, GLP-1 receptor agonists, GIP receptor agonist, energy balance
- MeSH terms
- Adipose Tissue, Animals, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Humans, Insulin Resistance, Obesity, Signal Transduction, Glucagon-Like Peptide 1, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance. https://app.cochat.ai/papers/10.3390/ijms25168650
- The paper
- De Fano, M., Malara, M., Vermigli, C., & Murdolo, G. (2024). Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25168650
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.